Valor-Hcm Results

ACC 22: Findings from the VALOR-HCM Trial | Dr Milind Y Desai

ESC TV at #ACC22 - Expert Insights on VALOR-HCM and MAVA-LTE Study

European Society of Cardiology

VALOR-HCM: Mavacamten in Obstructive Hypertrophic Cardiomyopathy

Discussing the VALOR-HCM Trial

After Shocks with Dr. Milind Desai on the VALOR-HCM trial

New York State Chapter of the American College of Cardiology

VALOR-HCM Shows Promise for Patients With Hypertrophic Cardiomyopathy (for Healthcare Professionals)

Cleveland Clinic

Cardiac Myosin Inhibitors and HCM: Therapy of the (Near) Future

Cardiology University of Washington

Mavacamten for HCM

Cardiomyopathy UK

Clinical Trial Shows Drug is Effective in Nearly 80% of Patients with Hypertrophic Cardiomyopathy

Cleveland Clinic

ESC 2020 Discussion: The EXPLORER-HCM Study— Dr Iacopo Olivotto & Dr Harriette Van Spall

ACC CVRI: Journal Club: VALOR-HCM Trial - By Tess Calcagno

ACC Medical Student Member Community

Drug Reduces the Need for Surgery in Nearly 90% of Patients with HCM, Cleveland Clinic Study Shows

Cleveland Clinic

HCM study

Cardiomyopathy UK

New Evidence on Cardiac Myosin Inhibition in Hypertrophic Cardiomyopathy

#CardioGuy #Mavacamten #cardio #cardiology #cardiomyopathy #medicine #study #randomized #trail #usa

EXPLORER-HCM trial results - Daniel Jacoby, MD

Current and Evolving Understanding in Hypertrophic Cardiomyopathy

Cleveland Clinic

Pushing Back Against HCM: The Role of Cardiac Myosin Inhibitors

What is Hypertrophic Cardiomyopathy

The EXPLORER-HCM study: mavacamten for obstructive HCM

Video Journal of Biomedicine